Safely Managing Antibiotics Through Procalcitonin Measurement
Recorded On: 09/29/2022
This sponsored session will discuss how measuring procalcitonin (PCT) in patients with sepsis can help healthcare professionals to establish the concept of bacterial burden, safely manage antibiotics, and improve clinical and financial outcomes. Learners will review the diagnostic and treatment dilemmas associated with the management of sepsis, as well as the high-level pathophysiology, kinetics, and advantages of procalcitonin in comparison to traditional biomarkers of infection. Case studies illuminating the appropriate application of PCT for safely reducing antibiotic exposure will ground viewers in skills they can apply to their practice. Lastly, a brief analysis of clinical and financial outcomes should motivate learners to consider the use of PCT in their patient care.
This session was originally recorded in September 2022 as part of Sepsis Alliance Summit.
No CE credits are offered for this sponsored session. Content was determined by the sponsor.
Sepsis Alliance gratefully acknowledges the support provided by Siemens Healthineers for this sponsored session.
Michael Broyles, PharmD
Director of Medical Affairs, Biomarkers
Mike Broyles, PharmD has more than 30 years of experience as a Hospital Pharmacy and Laboratory Director providing patients with current concepts in the clinical use of drugs with a focus on antimicrobial stewardship. His current role is Director of Medical Affairs, Biomarkers for Thermo Fisher Scientific. Prior to joining Thermo Fisher Scientific, Mike had more than 25 years consulting for a large IHN as their pharmacy advisory chairman to develop and implement clinical initiatives. His goal is to provide the leading thought processes in patient management and use technology to enhance the ability of clinicians to have the best options in patient’s clinical status, decision support, and improving outcomes through better clinical care.